tirzepatide and lithium (Mounjaro) Lilly releases Zepbound® (tirzepatide) single-dose

What makes this moment in the GLP-1 pipeline notable is the convergence: a biweekly injectable showing Phase 2b results, a monthly injectable candidate in Phase 2b trials, and multiple oral formulations now in or entering Phase 3

Simultaneously, it suppresses the release of glucagon, a hormone that raises blood glucose levels

No prospective randomized trials are available on this matter

Energy availability is lower, recovery capacity is often reduced, and the priority shifts from "burn more calories" to "send the strongest possible signal to preserve muscle" with the least metabolic cost

There [were] harvests and then famines